Tvardi Therapeutics (NASDAQ:TVRD) Stock Price Up 0.2% – Here’s What Happened

Tvardi Therapeutics, Inc. (NASDAQ:TVRD)’s share price rose 0.2% on Tuesday . The stock traded as high as $35.20 and last traded at $33.83. Approximately 32,459 shares changed hands during trading, an increase of 47% from the average daily volume of 22,091 shares. The stock had previously closed at $33.76.

Wall Street Analysts Forecast Growth

TVRD has been the subject of several research analyst reports. Raymond James Financial initiated coverage on shares of Tvardi Therapeutics in a research note on Monday, July 14th. They set an “outperform” rating and a $62.00 price target for the company. Oppenheimer initiated coverage on shares of Tvardi Therapeutics in a research note on Wednesday, May 21st. They set an “outperform” rating and a $65.00 price target for the company. Wall Street Zen raised shares of Tvardi Therapeutics to a “hold” rating in a research note on Saturday, May 24th. Piper Sandler began coverage on shares of Tvardi Therapeutics in a research note on Thursday, June 12th. They set an “overweight” rating and a $78.00 price target for the company. Finally, Cantor Fitzgerald began coverage on shares of Tvardi Therapeutics in a research note on Friday, July 11th. They issued an “overweight” rating and a $52.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $64.25.

Tvardi Therapeutics Stock Performance

The stock has a 50 day moving average of $27.32.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings results on Thursday, August 14th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.49). Tvardi Therapeutics had a negative return on equity of 565.83% and a negative net margin of 678.79%.

Hedge Funds Weigh In On Tvardi Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. purchased a new position in Tvardi Therapeutics in the second quarter worth $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Tvardi Therapeutics in the second quarter worth $43,000. Headlands Technologies LLC purchased a new position in Tvardi Therapeutics in the second quarter worth $80,000. New York State Common Retirement Fund purchased a new position in Tvardi Therapeutics in the second quarter worth $92,000. Finally, Bank of America Corp DE purchased a new position in Tvardi Therapeutics in the second quarter worth $399,000. 44.66% of the stock is owned by hedge funds and other institutional investors.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.